A Phase III Trial of One Vs. Two Years of Maintenance Olaparib, with or without Bevacizumab, in Patients with BRCA1/2 Mutated or Homologous Recombination Deficient (HRD+) Ovarian Cancer Following Response to First Line Platinum-Based Chemotherapy

Protocol No
NRG-GY036
Staff Member
William Bradley
Phase
III
Summary

We are doing this study because we want to find out if taking olaparib as maintenance for one year is as good or worse than the usual approach of taking olaparib for two years for ovarian cancer patients. Giving olaparib for one year with or without bevacizumab may be as effective in treating patients with BRCA 1/2 mutated or homologous recombination deficient stage III or IV ovarian cancer, when compared to two years of olaparib.

Objective
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer.
Status
OPEN TO ACCRUAL